Know Cancer

or
forgot password

Proposed Study of CLL Samples


N/A
18 Years
N/A
Not Enrolling
Both
Leukemia

Thank you

Trial Information

Proposed Study of CLL Samples


OBJECTIVES:

- To analyze the expression of a variety of informative molecules using a unique
high-resolution flow cytometric immunophenotyping technology in samples from patients
with chronic lymphocytic leukemia enrolled in clinical trial ECOG-2997.

OUTLINE: Cell samples are analyzed for the following prognostic biomarkers: ZAP-70,
phospho-Syk, phospho-GSK-3╬▓, phospho-Akt, phospho-ZAP-70, cyclin D1, cyclin D2, p21cip1,
phospho-ReIA, IkappaB╬▒, Bax, Mcl-1, PTEN, phospho-Erk1/2, and phospho-MEK1/2. Biomarker
signals are amplified using enzymatic amplification staining to obtain high resolution
detection of cell-surface markers on leukemic cells. Biomarker expression levels are
measured using fluorescence activated cell sorting analysis. Relationships between clinical
outcomes, standard flow cytometric analysis, cytogenetic studies, and high resolution
immunophenotyping will also be assessed.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Stored frozen viable cells from patients with chronic lymphocytic leukemia treated on
clinical trial ECOG-2997

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Correlation of biomarker analysis with complete response

Safety Issue:

No

Principal Investigator

David Kaplan, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

University Hospitals Seidman Cancer Center

Authority:

Unspecified

Study ID:

CDR0000617494

NCT ID:

NCT00899873

Start Date:

August 2008

Completion Date:

Related Keywords:

  • Leukemia
  • chronic lymphocytic leukemia
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid

Name

Location